|This activity is available for free to members of NASP. Visit the top section of www.ProCE.com/CSPE for details.|
According to the American Cancer Society, Colorectal cancer (CRC) is the third most common cancer diagnosis in the United States. It is also the third leading cause of cancer deaths. Early detection of CRC is a major key to survival and cure. This educational activity will provide an overview of the epidemiology, risk factors, pathology, and staging of CRC. Common treatments used for CRC will be reviewed along with a discussion of adverse effects and recommended monitoring. Strategies to improve the compliance and adherence in CRC patients will also be discussed.
The target audience for this activity includes pharmacists. Upon completion of this activity, participants will be able to:
- Describe the epidemiology, risk factors, and pathology of colorectal cancer
- Discuss the screening, diagnosis, and staging of colorectal cancer
- Outline typical treatment regimens for adjuvant and metastatic colorectal cancers
- Describe the side effect and monitoring parameters associated with oral chemotherapy and targeted treatments in colorectal cancer
- Discuss counseling strategies to maximize compliance and adherence
Sal Bottiglieri, PharmD, BCOP
Clinical Pharmacy Coordinator, Medical Oncology
Moffitt Cancer Center
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants the existence of any significant financial interest or any other relationship with the manufacturer of any commercial product(s) discussed in an educational presentation. Sal Bottiglieri has served as a speaker for Merck, and is an Advisory Board member for Array bBiopharma, Eisai, and the Cancer Support Community..
Release Date: 03-23-2020
Expiration Date: 03-23-2023
This CE activity is jointly provided by ProCE, Inc. and the National Association of Specialty Pharmacy (NASP). ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-20-203-H01-P has been assigned to this knowledge-based, home-study activity. This CE activity is approved for 1.25 contact hour (0.125 CEU) in states that recognize ACPE providers, and is provided at no cost to participants. Completion of an evaluation and post-test with a score of 70% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.
No external support has been received for this activity.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.